Dr Frank Waldron-Lynch is currently Clinical Senior Research Associate with the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory at the University of Cambridge, and Honorary Academic Consultant Endocrinologist with Cambridge University Hospitals NHS Foundation Trust. His primary research interest is the immunomodulatory therapy of type 1 diabetes. Dr Waldron-Lynch read medicine at the University of Cambridge graduating in 2002. Prior to medical school he trained as a research scientist receiving a B.Sc. in Biochemistry from the National University of Ireland, Galway and subsequently a Ph.D. in Immunogenetics from University College Cork. After house officer jobs at Addenbrooke’s Hospital, Cambridge he returned to Ireland for general and higher speciality training in endocrinology, diabetes and internal medicine at University College Hospital Galway and the Adelaide & Meath Hospital, Dublin. To complete his training he moved to Yale University School of Medicine in 2008. Whilst an endocrine fellow at Yale he participated in the design and supervision of clinical trials of immunomodulatory therapy to prevent the development of type 1 diabetes or treat at diagnosis. At Cambridge, he has developed with colleagues a novel translational medicine programme for treatment of type 1 diabetes that systematically targets immunotherapy to the key aetiological pathways that have been identified from genetic and immunology studies (http://www.clinical-trials-type1-diabetes.com).
Abstracts this author is presenting: